



Figure S1 CONSORT diagram of the study. LS-SCLC, limited-stage small cell lung cancer; EP, etoposide and platinum; ICIs, immune checkpoint inhibitors.

Table S1 Baseline characteristics of all patients

Characteristics	Subcategories	All patients (n=150), n (%)
Age (years)	<65	82 (54.67)
	≥65	68 (45.33)
Sex	Male	128 (85.33)
	Female	22 (14.67)
Smoking history	Never	36 (24.00)
	Former/current	114 (76.00)
ECOG PS	0	60 (40.00)
	1	90 (60.00)
Primary site	Left	66 (44.00)
	Right	84 (56.00)
N stage	N0	13 (8.67)
	N1	7 (4.67)
	N2	89 (59.33)
	N3	41 (27.33)
TNM stage	I–II	10 (6.67)
	III	140 (93.33)
Radiotherapy [†]	No	58 (38.67)
	Yes	92 (61.33)
Thoracic chemoradiation	No	60 (40.00)
	Concurrent	58 (38.67)
	Sequential	32 (21.33)
PCI	No	141 (94.00)
	Yes	9 (6.00)
Therapy	EP	87 (58.00)
	EP + PD-1 inhibitors	45 (30.00)
	EP + PD-L1 inhibitors	18 (12.00)

[†], radiotherapy included first-line thoracic radiotherapy and PCI. ECOG PS, Eastern Cooperative Oncology Group performance status; N stage, node stage; TNM, tumor node metastasis; PCI, prophylactic cranial irradiation; EP, etoposide and platinum; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1.